Abstract
These modifications occur in the Golgi apparatus via a series of N-deacetylases/Nsulfotransferase (NDST), sulfotransferases and a C5-epimerase. HS and heparin biosynthetic processes were first described by Lindahl in 1977 2 and since then it has been assumed that the enzymatic processing, ultimately resulting in unique substitution patterns, occurs through a hierarchical sequence of enzymatic events 2 where NDST is followed by C5-epimarese, 2-O-sulfotransferase, 6-O-sulfotranferase and, lastly, 3-O-sulfotransferase.
The presence of HS biosynthesis enzymes in organisms is related strongly to the emergence of multicellularity and tissue organization, being a characteristic of eumetazoan lineage 3, 4 . Moreover, a correlation between the complexity of an organism and the number of HS sulfotransferase isoforms is evident. For instance, the primitive organism C. elegans has just one isoform for each of the five known sulfotransferases, while humans have four NDSTs, one C5-epimerase, one HS2ST, three HS6STs and seven HS3STs 3 . Interestingly, rudimentary HS biosynthesis enzymes were found in unicellular and colony-forming organism M. brevicollis, suggesting that GAGs could have a key role in the emergence of multicellularity through extracellular organization and establishment of cell-cell communication 3 .
HS and heparin are known to regulate a wide range of physiological processes 5 and heparin is employed for its pharmacological activity in cardiovascular medicine as an anticoagulant and antithrombotic drug 6 since it modulates antithrombin (AT), the principal physiological inhibitor of the coagulation in vertebrates. The sequence in heparin which is thought principally responsible for this activity corresponds to a pentasaccharide ANAc/NS,6S-G-ANS,3S,6S-I2S-ANS,6S (AGA*IA), found on average in onethird of the heparin chains 7 . This specific sequence was described following fractionation of heparin by affinity chromatography, which revealed that AT high-affinity fractions had 3-O-sulfated glucosamine 8 . From then on, this modification has been considered the key for AT-binding 9, 10 , since pentasaccharide sequences lacking 3-Osulfated glucosamine have decreased in affinity for AT 10 , even though the presence of 3-O-group in central glucosamine is not essential to activate AT 9 since other GAGs and non-GAG based structures are able to activate AT 11, 12 .
Despite being unique and responsible for high-affinity AT-binding, different sequences and compounds, even non-carbohydrates, can exert the same effect [12] [13] [14] .
Furthermore, it is also important to highlight that under normal physiological conditions there is little circulating heparin, indicating that its biological function should be distinguished from its pharmacological use 1 . Furthermore, 3-O-sulfated glucosamine is yet to be found within commonly purified HS.
HS3ST is the largest sulfotransferase family in humans, although the simplest organism in which this enzyme has been reported is M. brevicollis 3 suggesting that, evolutionarily, 3-O-sulfated glucosamine could be the most ancient and has played an important role in the emergence of cellular communication. In addition, species that lack AT-mediated coagulation have heparin-like molecules containing high levels of 3-O-sulfated glucosamine with negligible anticoagulation activity [15] [16] [17] [18] . These data bring to light questions regarding the importance of the 3-O-sulfate group in AT activation and its role regarding the biological functions of HS.
In a previous study, a heparin-like polysaccharide from the shrimp L. vannamei exhibited a higher proportion of 3-O-sulfated glucosamine (A*) than mammalian heparin, however, this compound presented low anticoagulation activity 18 Chondroitin 4-sulfate (C4S, from bovine trachea), chondroitin 6-sulfate (C6S, from shark cartilage) and dermatan sulfate (DS, from porcine mucosa) were obtained from Sigma-Aldrich Co (St, Louis, MO, USA). Heparan sulfate (HS) from bovine pancreas was prepared according to 19 . Heparin (Hep) from porcine mucosa was obtained from Bioiberica S.A. (Barcelona, Catalunya, Spain), while chemically modified heparins were prepared as described in 20 . The two oligosaccharides were synthetized as described in 21 . Biosystems 3130 Genetic Analyzer.
Litopeneaus vannamei sulfotransferase (sHS) cloning

Protein expression and purification
After induction with 1mM IPTG, the protein expression was carried out in LB medium at 37°C for 1h and 200 rpm. The bacterial pellet was suspended in 10 mL of lysis buffer (50 mM NaH2PO4, pH 8.0, 500 mM NaCl, 1 mg/mL of lysozyme), incubated in ice for 30min and sonicated on ice using six 30-second bursts. Lysed cells were centrifuged (4000 x g for 20min, 4°C) and the supernatant was applied to a HisTrap HP column (GE Healthcare), previously equilibrated with native binding buffer (50 mM NaH2PO4, pH 8.0, 500 mM NaCl, 10 mM imidazole). The column was exhaustively washed with native wash buffer (50 mM NaH2PO4, pH 8.0, 500 mM NaCl, and 40 mM imidazole) and the recombinant protein was eluted with native elution buffer (50 mM NaH2PO4, pH 8.0, 500 mM NaCl, 250 mM imidazole). Fractions were pooled and bufferexchanged to phosphate-buffered saline using PD-10 desalting column (GE Healthcare). The recombinant protein was stored at -20°C.
In silico analysis
The similarity of HS/Hep sulfotransferases from human to the cloned-sequence from the L. vannamei was analyzed by MUSCLE (Multiple Sequence Alignment) from EMBL-EBI (http://www.ebi.ac.uk/Tools/msa/muscle/). Furthermore, structure protein prediction was performed using PHYRE2 Protein Fold Recognition Server program (http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi? id=index).
Recombinant sHS activity assay
Glycosaminoglycan substrate
Sulfotransferase activity was determined by incubating 40 µL of purified recombinant enzyme (0.05 µg/µL) with 100 µg of acceptor substrates and 50000 cpm were incubated at 37°C overnight and stopped by heating at 100°C for 1min. The 35 Slabeled products were examined by agarose gel electrophoresis.
Oligosaccharides substrates
The activity of sHS was also analyzed using two oligosaccharides (G-ANAc and I2S-ANS)
as acceptor substrates in order to confirm the specificity of recombinant enzyme to 
Agarose gel electrophoresis (PDA)
All reactions products were submitted to agarose gel electrophoresis as previously described by Dietrich and Dietrich, 1976 22 . Briefly, 25 µg of each acceptor (5 µL) was applied to a 0.55% agarose gel in 0.05 M 1,3-diaminopropane-acetate buffer, pH 9.0 and subjected to electrophoresis at 100 V for 1h. The gels were fixed with 0.1% cetyltrimethylammoinum bromide (CETAVLON) solution for 2h, dried and stained with toluidine blue solution (0.1% toluidine blue in 1% acetic acid in 50% ethanol), destained with 1% acetic acid in 50% ethanol solution. Subsequently, the gels were exposed for three days to radiation sensitive films and developed in Cyclone Storage Phosphor System (Packard Instrument Company INC., Groningen, Netherlands).
NMR spectroscopy
Prior to NMR experiments, the 35 S-labeled HepNSulfo was purified. Briefly, to the sample was added trichloroacetic acid 90% (10% of sample volume) and, after 30 min on ice, the sample was centrifuged and the supernatant was collected. 2 volumes (v/v) of methanol were added and, after 24h at -20 °C, the precipitate formed was collected by centrifugation (10000 x g for 15min at 4 °C), dried and suspended in 0. 
Differential scanning fluorimetry (DSF)
The capacity of 35 S-labeled products to stabilize antithrombin was analyzed as described by Lima et al., 2013 11 . Human antithrombin (AT) (1 mg/mL), previously purified from citrate plasma on a heparin-Sepharose column, was incubated with different substrates in the presence of SyproOrange TM dye (Invitrogen). Firstly, the dye was diluted in water (1 sypro:50 water (v/v)) and 3.5 µL was added to the mixture reaction in PBS buffer. The dye has an excitation wavelength of 300 nm or 470 nm and emits at 570 nm when bound to hydrophobic residues. Different substrates used were 25 µg of unfractionated heparin (UFH) (10 mg/mL), 62.5 µg of Arixtra pentasaccharide (ANS,6S-G2OH-ANS,6S,3S-I2S-ANS,6S-OMe) (12.5 mg/mL), 25 µg of each modified heparin and 25 µg of 35 S-labeled modified heparins, previously analyzed by PDA. Reactions were incubated at 31°C for 2 min, and, then they were subjected to a step-wise temperature gradient from 32 to 85°C in a 0.5°C steps. Between each temperature step, there was a 5s incubation period to equilibrate samples. Reactions were developed at 7500 Real Time PCR System (Applied Biosystems) in triplicate. The final curves were generated employing the first derivative of the melting curves.
Results
Phylogenetic analysis of sHS from Litopenaeus vannamei
After cloning and sequencing the sHS from shrimp, the amino acid sequence was predicted using Expasy software: SIB Bioinformatics Resouce Portal through the Translate tool ( Figure 1A and S1). Figure 1 shows the sHS domains responsible for the carbohydrate and PAPS binding, which are shown in red in the cloned region.
Furthermore, comparative analyses were performed, including all HS sulfotransferases from Homo sapiens. These nucleotide and amino acid sequences were obtained from
PubMed-NCBI and UniProteinKB databases respectively and aligned using MUSCLE ( Figure 1B and 1C) . The analysis showed that the heparan sulfate 3-Osulfotransferase family from Homo sapiens (hHS3ST) exhibited homology with sHS, the isoforms 1 and 5 being the closest, and are those thought to be responsible for anticoagulant HS production. Protein 3D structure was modeled using PHYRE2 Protein Fold Recognition Server, shown in Figure 1D , which highlights the significant structural similarity between sHS and the human heparan sulfate 3-O-sulfotransferase isoform 5.
Substrate selectivity for sHS a. Broad selectivity assays
Heparan sulfate 3-O-sulfotransferase transfers sulfate from PAPS (adenosine 3′- Nevertheless, only the HepNSulfo [35] S-sulfate showed a signal at 5.5/99.5 ppm that corresponds to ANS,6X,3S, indicating that sHS was able to transfer the sulfate from PAPS to C3-glucosamine ( Figure 2B ).
3-O-sulfotransferase in the HS biosynthesis pathway a. Hierarchical vs non-hierarchical biosynthesis
We further tested the sHS substrate recognition using two octasaccharides (G-ANAc and I2S-ANS) as substrates for the enzyme. As observed in Figure 3 16, 18 . A tree structure for the biosynthesis of the major heparin and HS disaccharides has been proposed 24 . Here, this scheme is expanded and, again,
shows that heparin and HS biosynthesis as a whole cannot be described fully using the original description proposed by Lindahl 2 .
Thermostabilizing effects of sHS-treated heparins on AT
As described by Lima et al, 2013 [22] , the anticoagulant activity of heparin is correlated with the extent to which the complex between the polysaccharide and AT is stabilised, rather than by the secondary structural changes induced in AT by heparin binding. In order to analyze whether the addition of 3-O-sulfate groups induced further AT stabilization, AT was incubated with a range of different substrates and thermostabilization was measured using differential scanning fluorimetry (DSF) ( Figure   5 ). Only unfractionated heparin (UFH) and the pentasaccharide sequence, classical anticoagulant drugs, stabilized AT (61,75°C and 65,75°C respectively) whereas heparins [35] S-sulfate, previously modified by sHS, were unable to do so ( Figure 5 ). This shows that a 3-O-sulfate group can be introduced into the polysaccharide but, this does not necessarily bestow stabilization on AT, or imply activity.
Discussion
The first description of 3-O-sulfated glucosamine residues in heparin were suggested by Danishefsky et al., 1969 25 when, according to methylation analyses, the authors proposed that heparin contained small proportions of 3,6-di-Osulfoglucosamine. Owing to the fact that 3-O-sulfation is a rare modification in heparin 26 and also in HS 27 coupled to the absence of widely available methodologies able to evaluate such a modification, it is challenging to determine the real role and extent of this modification in HS and heparin biosynthetic and biological properties.
Since the discovery of 3-O-sulfate groups in heparin with high-affinity for antithrombin 8 , this modification has been considered crucial to the pharmacological role of heparin since the presence of 3-O-sulfation in the central glucosamine of the pentasaccharide (AGA*IA) increases 1000-fold the heparin binding for AT 10 .
Nonetheless, besides the presence of 3-O-sulfated glucosamine, several other structural features of heparin have been reported to influence in AT activity 10, 14, [28] [29] [30] .
In this study, we cloned and characterized a sulfotransferase from the shrimp L.
vannamei similar to the isoforms 1 and 5 from Homo sapiens. The results suggest that this cloned enzyme is able to transfer sulfate to C3 position of glucosamine and, since these isoforms are responsible for their production 31, 32 , also produce anticoagulant polysaccharides. The identity of the 3-O-sulfotransferase was confirmed by radiolabeling activity assays and NMR spectroscopy.
According to the classical HS biosynthesis 33 , HS chain modification occurs hierarchically, meaning that 3-O-sulfotransferase is the last enzyme to modify the HS chains. Nevertheless, both HepNAc or G-ANAc compounds, which show only Nacetyated glucosamine in their structure, were modified by sHS, indicating that the HS sulfotransferases could act on substrates independent of this sequential route 14, 24 , which emphasizes that 3-O-sulfotransferase works at different steps of the biosynthetic process. It is important to highlight that organisms such as M. brevicollis, which were the first organisms to exhibit HS sulfotransferases, have only HS2ST and HS3ST.
Furthermore, it has also been suggested that the epimerase enzyme appears evolutionarily later in a development 3 . Hence, 3-O-sulfated heparin/HS can be biosynthesized through different pathways.
It has been demonstrated that the high affinity of heparin towards AT requires a pentasaccharide sequence that contains a 3-O-sulfate group in a central glucosamine unit 10, 34 . However, our results show that the 3-O-sulfated chemically modified heparins
were not able to further stabilize AT, compared to their untreated counterparts, suggesting that the presence or abundance the 3-O-sulfation is not, in itself, sufficient to provide anticoagulant activity 9, 18 . One may argue that the 3-O-sulfation of the studied polysaccharides is too low to promote AT stabilization but it is important to highlight that these modification themselves, even within pharmaceutical heparins, are indeed low and, in our work, they were high enough to be detected by NMR, that is, at least 2-3%. Moreover, previous studies have already shown that the presence of 3-Osulfated groups in heparan is not essential for normal hemostasis, since Hs3t1 -/ -knockout mice did not exhibited a pro-coagulant phenotype 35 , questioning the role of this modification: other heparin features are relevant for such events 18 .
In summary, our data show that 3-O-sulfate groups are not solely responsible for AT stabilization and that 3-O-sulfotransferases can work in a non-hierarchical fashion during the HS/Heparin biosynthetic process.
